Cognition Therapeutics Reports Officer Changes and Compensation Arrangements
Ticker: CGTX · Form: 8-K · Filed: Feb 20, 2024 · CIK: 1455365
| Field | Detail |
|---|---|
| Company | Cognition Therapeutics INC (CGTX) |
| Form Type | 8-K |
| Filed Date | Feb 20, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Cognition Therapeutics just filed an 8-K about changes in their leadership and how they're paying their execs, so keep an eye out for potential strategic shifts!**
AI Summary
Cognition Therapeutics, Inc. filed an 8-K on February 20, 2024, reporting an event that occurred on February 15, 2024. The filing pertains to the departure or election of directors or certain officers, as well as compensatory arrangements for certain officers. The company, incorporated in Delaware, has its business address at 2500 Westchester Ave., Purchase, NY 10577.
Why It Matters
Changes in executive leadership and compensation can signal strategic shifts or financial health, impacting investor confidence and future company direction.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty, but the specific details are not yet disclosed to fully assess the impact.
Key Players & Entities
- COGNITION THERAPEUTICS INC (company) — Filing registrant
- February 15, 2024 (date) — Date of earliest event reported
- February 20, 2024 (date) — Filing date
- Delaware (company) — State of incorporation
- 2500 Westchester Ave. Purchase , NY 10577 (company) — Business address
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 15, 2024.
When was this 8-K filed with the SEC?
This 8-K was filed with the SEC on February 20, 2024.
What specific items are covered in this 8-K filing?
The 8-K covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'.
What is the full name of the registrant company?
The full name of the registrant company is Cognition Therapeutics, Inc.
Where is Cognition Therapeutics, Inc. incorporated?
Cognition Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 575 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-02-20 16:44:25
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share CGTX The Nasdaq Stock Mar
Filing Documents
- tm246515d1_8k.htm (8-K) — 26KB
- tm246515d1_ex10-1.htm (EX-10.1) — 35KB
- 0001104659-24-025580.txt ( ) — 238KB
- cgtx-20240215.xsd (EX-101.SCH) — 3KB
- cgtx-20240215_lab.xml (EX-101.LAB) — 33KB
- cgtx-20240215_pre.xml (EX-101.PRE) — 22KB
- tm246515d1_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 15, 2024, the Board of Directors of Cognition Therapeutics, Inc. (the " Company "), based upon the recommendation of the Compensation Committee, granted certain Performance Restricted Stock Units (" PSUs ") to employees and officers of the Company, including (i) Lisa Ricciardi, the Company's Chief Executive Officer, (ii) John Doyle, the Company's Chief Financial Officer, and (iii) Anthony Caggiano, the Company's Chief Medical Officer. Ms. Ricciardi was awarded 150,000 PSUs, Mr. Doyle was awarded 60,000 PSUs and Dr. Caggiano was awarded 130,000 PSUs. The PSUs will vest in two equal installments, in each case, upon the one year anniversary of the achievement of certain clinical milestones. The foregoing description of the PSUs does not purport to be complete and is subject to, and qualified in its entirety by, the form of Performance Restricted Stock Unit Award Agreement, which is filed and attached hereto as Exhibit 10.1, and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits The following exhibits are being filed herewith: (d) Exhibits Exhibit No. Document 10.1 Form of Performance Restricted Stock Unit Award Agreement. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 20, 2024 COGNITION THERAPEUTICS, INC. By: /s/ Lisa Ricciardi Name: Lisa Ricciardi Title: President and Chief Executive Officer